Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Transparency at the Food and Drug Administration.

Asamoah AK, Sharfstein JM.

N Engl J Med. 2010 Jun 24;362(25):2341-3. doi: 10.1056/NEJMp1005202. Epub 2010 May 19. No abstract available.

2.

Advisory committees" critical to the FDA's product review process.

Rados C.

FDA Consum. 2004 Jan-Feb;38(1):17-9. No abstract available.

3.

Increasing transparency at the FDA: the impact of the FDA Amendments Act of 2007.

Wood SF, Perosino KL.

Public Health Rep. 2008 Jul-Aug;123(4):527-30. No abstract available.

5.

US advisory panellists on drug's safety had ties to manufacturers.

Lenzer J, Epstein K.

BMJ. 2012 Jan 10;344:e244. doi: 10.1136/bmj.e244. No abstract available.

PMID:
22234908
6.
7.

Debating the risks of drug-eluting stents.

Shuchman M.

N Engl J Med. 2007 Jan 25;356(4):325-8. No abstract available.

PMID:
17251527
8.

Keeping science on top in drug evaluation.

Avorn J.

N Engl J Med. 2007 Aug 16;357(7):633-5. No abstract available.

9.

Settling for second best?

Pitts PJ.

Nat Biotechnol. 2007 Jul;25(7):715-6. No abstract available.

PMID:
17621285
10.

CancerScope: FDA Advisory Committee supports second HPV vaccine.

Printz C.

Cancer. 2009 Nov 15;115(22):5130. doi: 10.1002/cncr.24728. No abstract available.

11.

A key role for FDA GI drug advisory committee in expedited reviews.

Lang L.

Gastroenterology. 2003 Aug;125(2):289. No abstract available.

PMID:
12891523
12.

Observational studies of drug safety--aprotinin and the absence of transparency.

Hiatt WR.

N Engl J Med. 2006 Nov 23;355(21):2171-3. No abstract available.

13.

Probity gone nuts.

[No authors listed]

Nat Biotechnol. 2007 May;25(5):483.

PMID:
17483818
14.

Blueprint for a stronger Food and Drug Administration.

Curfman GD, Morrissey S, Drazen JM.

N Engl J Med. 2006 Oct 26;355(17):1821. Epub 2006 Oct 9. No abstract available.

16.

Potential legal barriers to increasing CMS/FDA collaboration: the law of trade secrets and related considerations.

Wang SS, Smith JJ.

Food Drug Law J. 2003;58(4):613-27. No abstract available.

PMID:
15027453
17.

Let the spin begin. Greater transparency urged for device trials.

Becker C.

Mod Healthc. 2005 Mar 14;35(11):33. No abstract available.

PMID:
15794228
18.

Stent thrombosis redux--the FDA perspective.

Farb A, Boam AB.

N Engl J Med. 2007 Mar 8;356(10):984-7. Epub 2007 Feb 12. No abstract available.

19.

FDA advisory panel voices persistent safety concerns.

Finkelstein JB.

J Natl Cancer Inst. 2006 Apr 5;98(7):439. No abstract available.

20.
Items per page

Supplemental Content

Write to the Help Desk